Early Cancer Detection
Why Early Cancer Detection
Our Early Cancer Detection Blood Tests
Our Multiomics Platform
Clinical Evidence
Clinical Studies
Publications
About
About Us
Leadership
News
Blog
Contact Us
Partnerships
Partnership Opportunities
Careers
Open Positions
Early Cancer Detection
Why Early Cancer Detection
Our Early Cancer Detection Blood Tests
Our Multiomics Platform
Clinical Evidence
Clinical Studies
Publications
About
About Us
Leadership
News
Blog
Contact Us
Partnerships
Partnership Opportunities
Careers
Open Positions
Press Releases
2023
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
May 22, 2023
Freenome Adds University Of Chicago As A Partner For Its Vallania Study
April 12, 2023
Freenome Adds Renown Health As Partner For The Sanderson Study
March 28, 2023
Freenome Presents A Subject Population Analysis Of A Clinical Study Using A Multiomics Blood Test For The Early Detection Of Colorectal Cancer
March 6, 2023
Freenome Partners with Geisinger for the Sanderson Study
January 18, 2023
2022
Freenome Presents Research Highlighting The Promise of Identifying Drug-Response Biomarker for DLBCL Patients
December 12, 2022
Freenome Adds Several Community Partners to Clinical Study for the Early Detection of Cancer
November 1, 2022
Freenome Launches Study of Multiple Cancers Pairing Multiomics with Real-World Data
September 6, 2022
Freenome Continues Growth, Adds Three New Leaders
June 2, 2022
Freenome Research Underscores Clinical Utility of Screening Tests That Detect Adenomas
May 25, 2022
Freenome and Morehouse Present Research on Study Participation Among Black Patients
May 23, 2022
Largest Clinical Study Validating a Blood-based Colorectal Screening Test Completes Enrollment
May 10, 2022
Freenome and Merck KGaA, Darmstadt, Germany to Present Data on Combination of Multiomics Profiling and Computational Modeling at AACR Meeting
April 13, 2022
Freenome Presents Research That Highlights the Significance of Detecting Adenomas in Any Test That Screens for Colorectal Cancer
April 11, 2022
Lance Baldo Joins Freenome as Chief Medical Officer
April 4, 2022
Research Highlights Changing Factors that Influence Colorectal Cancer Screening Adherence
March 15, 2022
Freenome Launches the Vallania Study for the Early Detection of Multiple Cancers
February 28, 2022
Freenome Presents Research Highlighting its Multiomics Blood Testing Platform in PREEMPT CRC
January 24, 2022
Significant Investment Accelerates Freenome’s Multiomics Platform for the Early Detection of Cancer
January 11, 2022
2021
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
December 7, 2021
Freenome Partners with Siemens Healthineers for Breast Cancer Research
December 1, 2021
Morehouse School of Medicine and Freenome Present Research Demonstrating High Enrollment Rates for African Americans in Clinical Trial
October 27, 2021
Freenome Shows Continued Leadership in Colorectal Cancer Research
October 25, 2021
Research Shows the Clinical Benefits of Detecting Adenomas
June 7, 2021
Freenome Presents Data Revealing Signatures of Immune Checkpoint Inhibitor Treatment Response Found to Be Common Across Kidney, Melanoma, and Lung Cancers
April 10, 2021